{
    "ticker": "OPTX",
    "name": "Opthea Limited",
    "description": "Opthea Limited is a biopharmaceutical company focused on developing innovative treatments for eye diseases. Founded in 2002 and headquartered in Melbourne, Australia, Opthea is dedicated to addressing the significant unmet medical needs of patients suffering from retinal diseases, particularly age-related macular degeneration (AMD). The company\u2019s lead product candidate, OPT-302, is a novel therapy designed to target the underlying mechanisms of AMD, offering potential benefits over existing treatments by inhibiting specific pathways involved in disease progression. Opthea aims to improve the quality of life for patients through its clinical development programs, which are rigorously designed to evaluate the safety and efficacy of its therapies. The company is committed to scientific excellence and collaboration, working with leading research institutions and clinical centers to advance its pipeline. With a focus on innovation and patient-centric solutions, Opthea is positioning itself as a leader in the ophthalmic therapeutics market, striving to bring new hope to those affected by debilitating eye conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Melbourne, Australia",
    "founded": "2002",
    "website": "https://www.opthea.com.au",
    "ceo": "Dr. Megan Baldwin",
    "social_media": {
        "twitter": "https://twitter.com/OptheaLimited",
        "linkedin": "https://www.linkedin.com/company/opthea-limited/"
    },
    "investor_relations": "https://www.opthea.com.au/investor-relations",
    "key_executives": [
        {
            "name": "Dr. Megan Baldwin",
            "position": "CEO"
        },
        {
            "name": "Rachael O'Connor",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "OPT-302"
            ]
        }
    ],
    "seo": {
        "meta_title": "Opthea Limited | Innovative Retinal Disease Therapies",
        "meta_description": "Opthea Limited is a biopharmaceutical company dedicated to developing innovative therapies for retinal diseases, including age-related macular degeneration.",
        "keywords": [
            "Opthea",
            "Biopharmaceuticals",
            "Ophthalmic Therapies",
            "Age-related Macular Degeneration",
            "OPT-302"
        ]
    },
    "faq": [
        {
            "question": "What does Opthea do?",
            "answer": "Opthea is focused on developing innovative treatments for eye diseases, particularly age-related macular degeneration."
        },
        {
            "question": "Who is the CEO of Opthea?",
            "answer": "Dr. Megan Baldwin is the CEO of Opthea Limited."
        },
        {
            "question": "Where is Opthea headquartered?",
            "answer": "Opthea is headquartered in Melbourne, Australia."
        },
        {
            "question": "What is OPT-302?",
            "answer": "OPT-302 is Opthea's lead product candidate designed to treat age-related macular degeneration."
        },
        {
            "question": "When was Opthea founded?",
            "answer": "Opthea was founded in 2002."
        }
    ],
    "competitors": [
        "REGN",
        "RGEN",
        "BMY",
        "AMGN"
    ],
    "related_stocks": [
        "AAPL",
        "JNJ",
        "PFE",
        "MRNA"
    ]
}